AI-generated research brief — verify at source
GBE Combined with Desmopressin Achieves 88% Full Response in Childhood Enuresis
In a four-arm placebo-controlled trial of 398 children with monosymptomatic nocturnal enuresis, the combination of Ginkgo biloba extract and Desmopressin produced the highest full response rate at 88.3%, compared with 46.5% for Desmopressin alone, 24.8% for GBE alone, and 9.5% for placebo (p < 0.001). GBE also demonstrated independent efficacy through a distinct mechanism — enhancing sleep arousal — offering a new therapeutic option beyond standard antidiuretic treatment.
What Was Studied
This trial investigated whether Ginkgo biloba extract (GBE), administered alone or combined with Desmopressin, could reduce the number of wet nights per week in children with monosymptomatic nocturnal enuresis more effectively than Desmopressin monotherapy or placebo. Secondary outcomes examined whether GBE influenced sleep quality, arousal thresholds, and health-related quality of life — dimensions not addressed by antidiuretic therapy alone.
How It Was Studied
This was a double-blind, randomized, placebo-controlled trial enrolling 398 children aged 5 to 14 years who met criteria for monosymptomatic nocturnal enuresis. Participants were allocated equally across four arms: placebo, GBE 60 mg daily, Desmopressin 0.2 mg daily, or the combination of GBE plus Desmopressin. All treatments were administered for three months. Sleep quality was assessed using the Sleep Disturbance Scale for Children (SDSC), arousal using the Disorders of Arousal (DA) score, and quality of life using the Pediatric Incontinence Questionnaire (PinQ). Serum sodium was monitored as a safety measure.
What Was Observed
- Combination therapy produced the greatest reduction in wet nights, with a median of 0 wet nights per week (IQR 0–2) after three months — effectively eliminating enuresis episodes in a substantial portion of patients. By comparison, the Desmopressin group achieved a median of 2 wet nights (IQR 0–6) and the GBE group a median of 6 wet nights (IQR 0.5–6.5), with the difference across all groups being highly statistically significant (p < 0.001).
- Full response rates confirmed the hierarchy of treatment efficacy: the combination arm reached 88.3% full response (defined as ≥90% reduction in wet nights), followed by Desmopressin alone at 46.5%, GBE alone at 24.8%, and placebo at 9.5% (p < 0.001). Even GBE monotherapy showed meaningful activity well beyond placebo, suggesting genuine pharmacological effect.
- GBE-containing arms showed significantly increased arousal and lighter sleep, as reflected in higher DA and SDSC scores relative to non-GBE groups. This pattern suggests that GBE’s mechanism of action is distinct from Desmopressin’s antidiuretic effect, operating instead through modulation of sleep depth and the child’s capacity to wake in response to a full bladder.
- Quality of life improved across all active treatment groups, with PinQ scores declining (indicating improvement) most substantially in the combination arm. Adverse effects were mild and similarly distributed across groups, and serum sodium levels remained stable, supporting an acceptable short-term safety profile for GBE.
Why This Matters
Monosymptomatic nocturnal enuresis is a common pediatric condition, and Desmopressin — which works by reducing urine production — has been a mainstay of pharmacological treatment. This trial establishes GBE as a mechanistically distinct alternative that targets sleep arousal rather than urine volume, addressing a different physiological contributor to bedwetting. The finding that combining both agents nearly doubles the full response rate compared to Desmopressin alone suggests that treating multiple underlying mechanisms simultaneously may substantially improve outcomes for children who respond inadequately to standard therapy.
How to Read This Result
This well-powered, double-blind RCT provides strong initial evidence for GBE’s efficacy and safety in childhood enuresis over a three-month horizon, though the absence of reported long-term follow-up data means durability of response and relapse rates beyond the trial period remain unknown.
Limitations
The abstract does not explicitly report study limitations.